U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines (NASDAQ:ONC) was given a new $400.00 price target on by analysts at Truist Financial Corporation.
BeOne Medicines (NASDAQ:ONC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Royal Bank Of Canada from $395.00 to $408.00. They now have an "outperform" rating on the stock.